$GTBP News

GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives

EXCLUSIVE: GT Biopharma Sees Faster Discovery, Productivity Following AI Technology Rollout

EXCLUSIVE: GT Biopharma Sees Faster Discovery, Productivity Following AI Technology Rollout

Nasdaq Grants GT Biopharma Additional 180 Days To Regain Compliance

GT Biopharma Reports First Quarter 2026 Financial Results

GT Biopharma Q1 EPS $(0.11) Misses $(0.08) Estimate

GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors

EXCLUSIVE: GT Biopharma Begins Testing Of Lead Solid Tumor Drug Candidate Across Multiple Cancer Types

EXCLUSIVE: GT Biopharma Begins Testing Of Lead Solid Tumor Drug Candidate Across Multiple Cancer Types

GT Biopharma (GTBP) Upgraded to Buy: Here's What You Should Know

GT Biopharma (GTBP) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

GT Biopharma to Participate in the 38th Annual Roth Conference

GT Biopharma Reports Full Year 2025 Financial Results

GT Biopharma Q4 EPS $(4.84) Down From $(1.66) YoY

GT Biopharma Reported FY25 Net Loss Of $28.4M, Cash Balance Of ~$9M To Fund Operations Through The Fourth Quarter Of 2026

GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference

GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3

GT Biopharma Receives FDA Clearance Of Investigational New Drug Application For GTB-5550 TriKE

GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers

EXCLUSIVE: GT Biopharma Plans 2026 Trial For New Cancer Treatment